Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Markman

Showing results (411-420 of 545) with videos related to

Pageof 55
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 1991
Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatinM Markman, B Reichman, T Hakes, et al.
Gynecologic Oncology|August 6, 2000
Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcomaD M Kushner, K D Webster, J L Belinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1988
Phase I trial of concurrent intraperitoneal and continuous intravenous infusion of fluorouracil in patients with refractory cancerB Reichman, M Markman, T Hakes, et al.
Obstetrics and Gynecology|June 1, 1988
Peritoneal cytology as an indicator of disease in patients with residual ovarian carcinomaS C Rubin, E D Dulaney, M Markman, et al.
Gynecologic Oncology|November 5, 1997
High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-upF Shapiro, J Schneider, M Markman, et al.
Gynecologic Oncology|August 12, 1998
Phase 2 trial of moderately high dose single agent mitoxantrone in platinum and paclitaxel-refractory ovarian cancerM Markman, S M Lichtman, H Homesley, et al.
Gynecologic Oncology|December 22, 1999
Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trialM Markman, J A Blessing, K DeGeest, et al.
JACC. Case Reports|July 2, 2026
Transhepatic Access for Pulsed Field Ablation of Atrial Fibrillation Using a Dual-Energy Lattice-Tip CatheterMichael J Litt, Mohammad M Gad, Amir Heravi, et al.
Gynecologic Oncology|July 1, 1999
Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group studyJ S Berek, M Markman, J A Blessing, et al.
Heart Rhythm|May 16, 2024
Simplified approach to CO<sub>2</sub> insufflation for epicardial access using distal anterior interventricular vein exit without venographyMichael I Gurin, Gregory E Supple, Matthew C Hyman, et al.
Pageof 55

Showing results (411-420 of 545) with videos related to

Sort By:
Pageof 55
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 1991
Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatinM Markman, B Reichman, T Hakes, et al.
Gynecologic Oncology|August 6, 2000
Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcomaD M Kushner, K D Webster, J L Belinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1988
Phase I trial of concurrent intraperitoneal and continuous intravenous infusion of fluorouracil in patients with refractory cancerB Reichman, M Markman, T Hakes, et al.
Obstetrics and Gynecology|June 1, 1988
Peritoneal cytology as an indicator of disease in patients with residual ovarian carcinomaS C Rubin, E D Dulaney, M Markman, et al.
Gynecologic Oncology|November 5, 1997
High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-upF Shapiro, J Schneider, M Markman, et al.
Gynecologic Oncology|August 12, 1998
Phase 2 trial of moderately high dose single agent mitoxantrone in platinum and paclitaxel-refractory ovarian cancerM Markman, S M Lichtman, H Homesley, et al.
Gynecologic Oncology|December 22, 1999
Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trialM Markman, J A Blessing, K DeGeest, et al.
JACC. Case Reports|July 2, 2026
Transhepatic Access for Pulsed Field Ablation of Atrial Fibrillation Using a Dual-Energy Lattice-Tip CatheterMichael J Litt, Mohammad M Gad, Amir Heravi, et al.
Gynecologic Oncology|July 1, 1999
Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group studyJ S Berek, M Markman, J A Blessing, et al.
Heart Rhythm|May 16, 2024
Simplified approach to CO<sub>2</sub> insufflation for epicardial access using distal anterior interventricular vein exit without venographyMichael I Gurin, Gregory E Supple, Matthew C Hyman, et al.
Pageof 55